Journal
NEUROTHERAPEUTICS
Volume 19, Issue 6, Pages 1799-1817Publisher
SPRINGER
DOI: 10.1007/s13311-022-01313-9
Keywords
Peptide vaccines; Personalized immunotherapy; Glioma immunotherapy; Combinatorial immunotherapy; T cell therapy; Neoepitopes; Glioma antigens
Funding
- Projekt DEAL
Ask authors/readers for more resources
This article reviews recent clinical and translational advances in glioma immunotherapy, with a focus on targets and their cognate immune receptor derivatives as well as concepts to improve intratumoral T cell effector functions.
Gliomas are highly treatment refractory against immune checkpoint blockade, an immunotherapeutic modality that revolutionized therapy for many tumors. At the same time, technological innovation has dramatically accelerated the development of immunotherapeutic approaches such as personalized tumor-specific vaccine production, dendritic cell vaccine manufacture, patient-individual target selection and chimeric antigen receptor, and T cell receptor T cell manufacture. Here we review recent clinical and translational advances in glioma immunotherapy with a focus on targets and their cognate immune receptor derivates as well as concepts to improve intratumoral T cell effector functions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available